Trusted Resources
Amyloidosis is heterogeneous group of disorder characterized by extracellular deposition of misfolded insoluble proteinaceous material with cross beta pleated sheet…
These guidelines were written after an extensive literature search using MedLine publications from January 1980 to April 2021, under the terms "ATTR" AND "…
Transthyretin cardiac amyloidosis (ATTR-CA) is increasingly diagnosed owing to the emergence of noninvasive imaging and improved awareness. Clinical penetrance of…
Tafamidis is an effective treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), this study aimed to determine whether there is a differential effect between…
Hereditary Transthyretin Amyloidosis Polyneuropathy is a rare life-threatening neurologic disease that imposes considerable mortality and it is associated with…
To identify changes in the proteome associated with onset and progression of hereditary transthyretin-mediated (hATTR) amyloidosis, also known as ATTRv amyloidosis…
Hereditary transthyretin (hATTR) amyloidosis is a rare, systemic, progressive, debilitating, and fatal disease characterized by mutations in the gene encoding the…
The content of this study was presented at the annual meeting of the American Academy of Neurology, May 2019, Philadelphia, Pennsylvania; the Fifth Congress of the…
The outlook for transthyretin amyloidosis (ATTR) is changing with the availability of new and emerging treatments. ATTR now appears to be more common than…
Hereditary transthyretin (hATTR) amyloidosis is a rare, systemic, progressive, and life-threatening disease in which transthyretin proteins misfold and aggregate as…